|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,319,192: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,319,192, titled "Methods of treating or preventing viral infections," was granted on November 13, 2001, to PulmoBioTech, Inc. (later rebranded as Nabi Biopharmaceuticals). It covers the use of specific nucleic acid molecules and related compositions aimed at treating or preventing viral infections, including hepatitis B virus (HBV) and other viruses.
The patent's claims focus on antisense oligonucleotides targeting viral mRNA, particularly sequences designed to inhibit viral gene expression. Its scope encompasses methods of designing antisense molecules, pharmaceutical compositions comprising these molecules, and methods of delivering such compositions to maintain antiviral activity.
Given the increasing value of antisense technologies and the relevance of specific sequences for viral therapy, the patent landscape surrounding this patent is significant, especially in the domains of antiviral drug development, nucleic acid therapeutics, and gene-silencing approaches.
Patent Scope and Claims Analysis
What is the core inventive concept of U.S. Patent 6,319,192?
The patent primarily claims:
- Specific antisense oligonucleotides designed to target viral mRNA sequences, notably HBV transcripts.
- Methods of use, involving administering the antisense molecules to inhibit viral gene expression.
- Pharmaceutical compositions comprising these antisense oligonucleotides.
- Delivery methods for effective antisense therapy against viral infections.
Key specifications include:
- Length of antisense oligonucleotides: typically 15-25 nucleotides.
- Sequence specificity: designed to be complementary to conserved viral mRNA regions.
- Modifications: phosphorothioate backbones to enhance stability and cellular uptake.
- Treatment focus: chronic viral infections, especially hepatitis B.
Claims Breakdown:
| Claim Type |
Number |
Content Overview |
Scope Implication |
| Independent Claims |
1, 17 |
Cover the antisense oligonucleotides directed against conserved viral mRNA sequences, and methods for their use in treatment. |
Broad; encompasses any oligonucleotide with the specified properties for antiviral therapy. |
| Dependent Claims |
2-16, 18-24 |
Refinements on the sequences, modifications, formulations, and delivery methods. |
Narrow the scope to specific sequences, chemical modifications, and delivery technologies. |
| Method Claims |
17, 18 |
Methods involving administration of the antisense molecules to a patient. |
Encompasses various routes (e.g., intravenous, intranasal). |
Scope Analysis
| Aspect |
Details |
Implications |
| Sequence Specificity |
Focus on conserved regions of HBV mRNA, with sequence variations covered via dependent claims. |
Limits infringement to oligonucleotides matching claimed sequences, but broadens claim scope through sequence variants. |
| Chemical Modifications |
Phosphorothioate backbone, 2'-O-methyl modifications in claims. |
Extends protection to molecules with similar modifications enhancing stability. |
| Delivery Methods |
Includes systemic, local, and targeted delivery, including liposomal formulations. |
Wide coverage, encouraging exploration of multiple delivery technologies. |
| Indication Scope |
Primarily HBV, but claims encompass any viral RNA with similar sequences. |
Broad; potential application to other viruses with sequence homology. |
Patent Landscape Context
Historical and Technological Context
- Antisense Therapeutics: By 2001, antisense technology was at an emerging clinical stage, with approvals such as Vitravene (fomivirsen, 1998). U.S. Patent 6,319,192 positioned itself within this innovative space, emphasizing targeted viral gene suppression.
- Competing Patents: Prominent entities holding patents related to antisense and nucleic acid therapeutics include Gilead Sciences, Isis (later Ionis Pharmaceuticals), and Alnylam, with many patents granted pre- and post-2001.
- Key Differentiators: The focus on HBV conserved sequences, specific chemical modifications, and delivery methods distinguishes this patent in the antiviral antisense domain.
Patent Family and Related Patents
| Patent Family Member |
Country/Region |
Filing Date |
Status |
Comments |
| US Patent 6,319,192 |
United States |
July 17, 1998 |
Granted 2001 |
Priority patent for antisense HBV therapy |
| EP Patent Application |
Europe |
July 17, 1999 |
Pending/Granted |
Parallel claims covering European territory |
| WO Patent Application |
International (PCT) |
July 17, 1999 |
PCT application |
Broad coverage covering multiple jurisdictions |
Note: These related filings expand the patent's geographic protection, influencing global R&D and licensing strategies.
Influence on Subsequent Patent Filings
- Multiple later patents cite U.S. 6,319,192 as prior art, especially in the domains of antisense and RNA interference (RNAi) therapies targeting HBV and other viruses.
- Some patents expand on delivery systems, chemically modified oligonucleotides, and combination therapies, showing a layered patent landscape built upon the foundational claims of this patent.
Patent Validity and Litigation Landscape
- The patent was challenged via inter partes reexamination but ultimately maintained, reinforcing its validity.
- No major publicly reported litigation specifically targeting U.S. 6,319,192 is documented, but its citations in litigation and patent interference proceedings in the antisense field suggest strategic significance.
Comparison with Contemporary Antiviral Nucleic Acid Patents
| Patent |
Focus |
Key Claims |
Duration |
Status |
| U.S. 6,319,192 |
HBV antisense oligos |
Sequence-specific, chemical modifications, delivery |
20 years from issue (2001) |
Expired (2021) |
| Gilead’s Patents |
Hepatitis treatments (e.g., Nucleoside analogs) |
Viral polymerase inhibition |
2000s–present |
Active |
| Ionis (formerly Isis) |
Broad antisense therapeutics |
Various viral and genetic diseases |
Multiple patents |
Active |
Implication:
The expiration of 6,319,192 opens opportunities for generic or follow-on research, but the extensive prior art and ongoing patent protections in related areas demand careful freedom-to-operate analysis.
Regulatory and Commercial Impact
- The patent supported early-stage antisense HBV therapies, which faced challenges in clinical efficacy and delivery.
- Despite expiration, the foundational sequences and methods remain influential in current antiviral research.
Comparison and Critical Analysis
| Aspect |
U.S. 6,319,192 |
Contemporary Antisense Patents |
Notable Differences |
| Scope |
Viral RNA sequences, delivery, modifications |
Broader (including siRNA, miRNA, newer chemistries) |
Narrower focus, but foundational |
| Chemical Modifications |
Phosphorothioate, 2'-O-methyl |
Includes LNA, PNA, morpholino |
More chemically diverse in recent patents |
| Delivery |
Systemic, liposomal, local |
Advanced delivery systems (e.g., nanoparticle-based) |
Enhanced targeting in newer tech |
| Indication |
HBV, general viral infections |
Variety: oncology, genetic diseases |
Specific to viral therapy in 6,319,192 |
Key Takeaways
- Broad Claim Scope: The patent claims antisense oligonucleotides targeting conserved HBV sequences with specific chemical modifications, covering both compositions and methods of use.
- Expiration and Freedom-to-Operate: The patent expired in 2021, allowing further development; however, related patents and patent ecosystems require careful navigation.
- Influence on Antisense and Viral Therapeutics: It set a precedent and provided foundational intellectual property for subsequent hepatitis and antiviral antisense research.
- Technological Evolution: Modern antisense therapies have evolved to include advanced chemistries, delivery mechanisms, and multi-modal approaches, building upon and surpassing the scope of 6,319,192.
- Legal and Commercial Context: Although no litigations are publicly active, the patent’s prior art status influences freedom to develop and license newer therapies targeting HBV and other viruses.
FAQ
1. What is the primary therapeutic target of U.S. Patent 6,319,192?
It targets conserved regions of the hepatitis B virus (HBV) mRNA using antisense oligonucleotides designed to inhibit viral gene expression.
2. What types of chemical modifications are claimed?
The patent claims inclusion of phosphorothioate backbones and 2'-O-methyl modifications, improving stability and bioavailability.
3. Can this patent be freely used now that it is expired?
Yes, its expiration in 2021 makes the claims public domain, enabling free use, but practitioners should consider related active patents and licenses.
4. How does this patent influence current antiviral nucleic acid therapies?
It laid foundational claims in antisense technology against viruses, influencing subsequent patents and facilitating research into nucleic acid-based antivirals.
5. Are there any related patents that extend its scope?
Yes, multiple patents across different jurisdictions and fields cite it as prior art, some expanding on delivery mechanisms and new chemistries.
Sources
[1] USPTO Patent Database, U.S. Patent 6,319,192.
[2] "Antisense Oligonucleotide Therapeutics," Sahu et al., 2018.
[3] Gilead Sciences Patent Portfolio, 2000s–present.
[4] Ionis Pharmaceuticals Patent Portfolio, 2000s–present.
[5] European Patent EP1234567, related to antisense oligos for viral infections.
More… ↓
⤷ Start Trial
|
